Fut, nem toboroz2. fázis
Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder
A legfontosabb adatok
- Ki végzi
- Centre for Addiction and Mental Health
- Hol
- Kanada1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Fut, nem toboroz
- Fázis
- 2. fázis
- Résztvevők
- 36 fő, tervezett
- Kezdés
- 2024. aug. 16.
- Várható befejezés
- 2027. jan. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Oral solution
- A regiszteradat frissítve
- 2026. november 2.
Ki vehet részt
- Életkor
- 19 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- Meets DSM-5 criteria for AUD
- Meets drinking criteria of average weekly consumption > 10 standard drinks for women and > 15 standard drinks for men over the past 90 days
- Willing to take study medication and participate in laboratory sessions requiring self-administration of alcohol
- Agrees not to use cannabis or illicit drugs during the study period
- Able to communicate and provide informed consent in English
- Alanine Aminotransferase (ALT) and Aspartate Transaminase (AST) level should not be more than 2 times the upper normal limit, and bilirubin should not be more than 1.5 times the upper normal limit
- Enrolled in the Ontario Health Insurance Plan (OHIP)
- Willing and able to safely abstain from alcohol for at least 12 hours prior to the eligibility and alcohol self-administration visit
- Individuals who are capable of becoming pregnant: agree to the use of highly effective contraception during study participation and for an additional 28 days after the end of cannabidiol administration
Ki nem vehet részt
- Having any clinical condition, drug sensitivity, or prior therapy which, in the investigator's opinion, makes the participant unsuitable for the study
- Current medical conditions, prescriptions, or over the counter medications that interfere with receiving the study drug or alcohol (based on the study physician's assessment)
- Recent recreational drug use (assessed via urine toxicology screen) other than alcohol and nicotine products
- Currently in treatment for AUD (e.g. Alcoholics Anonymous, group therapy, individual therapy, on anticraving medication)
- History of severe alcohol withdrawal including withdrawal seizures, alcoholic hallucinosis, or delirium tremens
- Any history of seizures
- Serious unstable medical condition, including severe hepatic abnormalities
- Severe mental illness (e.g. active psychosis with ongoing delusions and/or hallucinations, active manic or hypomanic episodes, evidence of a major neurocognitive disorder, etc.) and other substance use disorders (moderate or severe; excluding tobacco use disorder) as determined by the qualified investigator
- History of hypersensitivity to CBD
- Clinical Institute Withdrawal Assessment (CIWA-Ar) score of 10 or above upon initial assessment
- Experiencing active suicidal ideation within the past 1 month and/or suicide attempt within the past 6 months
- Current use of CBD products or use of CBD products within the past month
- Self-report of significant alcohol-induced flushing after 1-2 drinks (a proxy for aldehyde dehydrogenase deficiency)
- Currently pregnant or breastfeeding or intending to become pregnant or breastfeed
- Currently institutionalized which refers to a person who lives in an institutional collective dwelling, such as a hospital, nursing home or prison, including a resident under custody (e.g., patient or inmate)
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This human laboratory study aims to assess the effects of cannabidiol on alcohol consumption and craving in participants with alcohol use disorder. In this double-blind within-subject placebo-controlled crossover trial, participants will be randomized to receive both cannabidiol and placebo with a 2-week washout period separating the two treatment phases.
A vizsgálat 2 csoportja
- CannabidiolA vizsgált kezelés
10-day supply of 600 mg of CBD, taken orally twice daily
Kezelés: Oral solution
- PlaceboPlacebo, összehasonlításként
10-day supply of 600 mg of placebo, taken orally twice daily
Kezelés: Oral solution
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder: A Human Laboratory Study
- A regiszteradat frissítve
- 2026. november 2.